DelveInsight’s, “T-Cell Lymphoma Pipeline Insight, 2023,” report provides comprehensive insights about 85+ companies and 85+ pipeline drugs in the T-Cell Lymphoma pipeline landscape. It covers the T-Cell Lymphoma pipeline drug profiles, including T-Cell Lymphoma clinical trials and nonclinical stage products. It also covers the T-Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For T-Cell Lymphoma emerging drugs, the T-Cell Lymphoma pipeline analysis report provides a 360° view of the T-Cell Lymphoma pipeline therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The T-Cell Lymphoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the T-Cell Lymphoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, T-Cell Lymphoma clinical trials studies, T-Cell Lymphoma NDA approvals (if any), and product development activities comprising the technology, T-Cell Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the T-Cell Lymphoma Pipeline Insight Report
- Over 85+ T-Cell Lymphoma companies are evaluating 85+ T-Cell Lymphoma pipeline therapies in various stages of development, and their anticipated acceptance in the T-Cell Lymphoma market would significantly increase market revenue.
- The leading T-Cell Lymphoma Companies includes Jazz Pharmaceuticals, Genor Biopharma, Solasia Pharma, Celgene, Celleron Therapeutics, Seagen, Nanjing Sanhome Pharmaceutical, Merck Sharp & Dohme, Medevir, Bristol Myers Squibb, Pfizer, Innate Pharma, Dizal Pharmaceutical, Hoffman-La-Roche, Affirmed, and others.
- Promising T-Cell Lymphoma Pipeline Therapies includes Belinostat, Pralatrexate Injection, HBI-8000, romidepsin (depsipeptide, FK228), Tenalisib, Romidepsin, Fostamatinib Disodium, E7777, Duvelisib, Chidamide, cyclophosphamide, adriacin, and others.
- The T-Cell Lymphoma Companies and academics are working to assess challenges and seek opportunities that could influence T-Cell Lymphoma R&D. The T-Cell Lymphoma pipeline therapies under development are focused on novel approaches to treat/improve T-Cell Lymphoma.
To explore more information on the latest breakthroughs in the T-Cell Lymphoma Pipeline treatment landscape of the report, click here @ T-Cell Lymphoma Pipeline Outlook
T-Cell Lymphoma Overview
T cell lymphomas (TCL) are a very heterogeneous group of lymphoid malignancies derived from mature T cells differing by localization, pathological features, and clinical presentation. T-Cell Lymphomas can develop in lymphoid tissues such as the lymph nodes and spleen or outside of lymphoid tissues (i.e., gastrointestinal tract, liver, nasal cavity, skin, and others). TCL represents approximately 12% of all non‐Hodgkin lymphomas (NHLs) and is divided into cutaneous TCL (CTCL) and peripheral TCL (PTCL), which themselves are subdivided into nodal or extranodal (systemic) types. Lymphomas that arise from mature T cells are sometimes categorized together under the general term peripheral T-Cell Lymphoma, distinguishing them from the lymphoma that arises from immature T cells or lymphoblastic lymphoma.
Latest Developmental Activities in the T-Cell Lymphoma Treatment Landscape
- The drug is currently being evaluated in Phase III clinical trials to treat patients with Peripheral T Cell Lymphoma. Solasia has begun preparing for the NDA Filing of SP-02.
- Geptanolimab (GB226) is an investigational, humanized, anti-PD-1 (IgG4) monoclonal antibody. National Medical Products Administration (NMPA) has accepted and granted priority review to new drug application (NDA) of geptanolimab for relapsed and refractory PTCL. The drug is in clinical studies to treat alveolar soft part sarcoma, cervical cancer, non-Hodgkin’s lymphoma, liver cancer, colorectal cancer, and non-small cell lung cancer. Genor BioPharma has development rights in China for GB226, and Apollomics retains worldwide rights to APL-501 (geptanolimab) outside of China.
For further information, refer to the detailed T-Cell Lymphoma Unmet Needs, T-Cell Lymphoma Market Drivers, and T-Cell Lymphoma Market Barriers, click here for T-Cell Lymphoma Ongoing Clinical Trial Analysis
T-Cell Lymphoma Emerging Drugs Profile
SP-02: Solasia Pharma
SP-02 (Darinaparsin) is a novel mitochondrial-targeted agent (organoarsenic) being developed for the treatment of various hematologic and solid cancers. In a US Phase II study, darinaparsin demonstrated clinical activity evidence in lymphoma, particularly PTCL. Furthermore, the Phase I study done in the US and the Pan-Asian Phase 1 study demonstrated positive efficacy and safety of SP-02. The drug is currently being evaluated in Phase III clinical trials to treat patients with Peripheral T Cell Lymphoma. Solasia has begun preparing for the NDA Filing of SP-02.
CC-486: Celgene
CC-486 (Azacitidine) is an orally-active form of Vidaza, a chemical analog of the cytosine nucleoside used in DNA and RNA. The main mechanism of action is thought to be hypomethylation of DNA and direct cytotoxicity to abnormal hematopoietic cells in the bone marrow. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. CC-486 is indicated for the treatment of acute myeloid leukemia in first remission. The drug is in Phase III clinical studies for the treatment of T-Cell Lymphoma.
IMC-001: ImmuneOncia Therapeutics
IMC-001 (STI-3031) is a fully human anti-PD-L1 IgG1 type monoclonal antibody that has shown promising results in terms of safety and efficacy in the dose-escalation first-in-human study although the patients were heavily pretreated. IgG1 type antibody targeting PD-L1 on tumor enables unique combinations, such as with an NK cell-based therapy, unique in its property among other PD-1/PD-L1 targeting agents.
Geptanolimab: Genor Biopharma
Geptanolimab (GB226) is an investigational, humanized, anti-PD-1 (IgG4) monoclonal antibody. National Medical Products Administration (NMPA) has accepted and granted priority review to new drug application (NDA) of geptanolimab for relapsed and refractory PTCL. The drug is in clinical studies to treat alveolar soft part sarcoma, cervical cancer, non-Hodgkin’s lymphoma, liver cancer, colorectal cancer, and non-small cell lung cancer. Genor BioPharma has development rights in China for GB226, and Apollomics retains worldwide rights to APL-501 (geptanolimab) outside of China.
Daratumumab: Janssen Research and Development
Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, highly expressed on the surface of multiple myeloma cells. Daratumumab triggers a person’s immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death). Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture, and commercialize daratumumab from Genmab.
T-Cell Lymphoma Pipeline Therapeutics Assessment
There are approx. 85+ key companies which are developing the therapies for T-Cell Lymphoma. The companies which have their T-Cell Lymphoma drug candidates in the most advanced stage, i.e. preregistration include, Genor Biopharma.
Request a sample and discover the recent advances in T-Cell Lymphoma Ongoing Clinical Trial Analysis and Medications, click here @ T-Cell Lymphoma Treatment Landscape
Scope of the T-Cell Lymphoma Pipeline Insight Report
- Coverage- Global
- T-Cell Lymphoma Companies- Jazz Pharmaceuticals, Genor Biopharma, Solasia Pharma, Celgene, Celleron Therapeutics, Seagen, Nanjing Sanhome Pharmaceutical, Merck Sharp & Dohme, Medevir, Bristol Myers Squibb, Pfizer, Innate Pharma, Dizal Pharmaceutical, Hoffman-La-Roche, Affirmed, and others.
- T-Cell Lymphoma Pipeline Therapies- Belinostat, Pralatrexate Injection, HBI-8000, romidepsin (depsipeptide, FK228), Tenalisib, Romidepsin, Fostamatinib Disodium, E7777, Duvelisib, Chidamide, cyclophosphamide, adriacin, and others.
- T-Cell Lymphoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for T-Cell Lymphoma Market Drivers and T-Cell Lymphoma Market Barriers, click here @ T-Cell Lymphoma Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- T-Cell Lymphoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Late Stage Products (Pre-registration)
- Geptanolimab: Genor Biopharma
- Drug profiles in the detailed report…..
- Late Stage Products (Phase III)
- SP-02: Solasia Pharma
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- IMC-001: ImmuneOncia Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Tolinapant: Astex Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- TTI-621: Trillium Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- BBI 3000: Brickell Biotech Inc
- Drug profiles in the detailed report…..
- Inactive Products
- T-Cell Lymphoma Key Companies
- T-Cell Lymphoma Key Products
- T-Cell Lymphoma- Unmet Needs
- T-Cell Lymphoma- Market Drivers and Barriers
- T-Cell Lymphoma- Future Perspectives and Conclusion
- T-Cell Lymphoma Analyst Views
- T-Cell Lymphoma Key Companies
- Appendix
Got Queries? Find out the related information on T-Cell Lymphoma Mergers and acquisitions, T-Cell Lymphoma Licensing Activities @ T-Cell Lymphoma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services